

REVIEW

Open Access



Rationale for MYC imaging and targeting in pancreatic cancer

Günter Schneider^{1,2,3*†} , Matthias Wirth^{2,4*†}, Ulrich Keller^{2,4,5} and Dieter Saur^{2,6}

Abstract

The incidence and lethality of pancreatic ductal adenocarcinoma (PDAC) will continue to increase in the next decade. For most patients, chemotherapeutic combination therapies remain the standard of care. The development and successful implementation of precision oncology in other gastrointestinal tumor entities point to opportunities also for PDAC. Therefore, markers linked to specific therapeutic responses and important subgroups of the disease are needed. The MYC oncogene is a relevant driver in PDAC and is linked to drug resistance and sensitivity. Here, we update recent insights into MYC biology in PDAC, summarize the connections between MYC and drug responses, and point to an opportunity to image MYC non-invasively. In sum, we propose MYC-associated biology as a basis for the development of concepts for precision oncology in PDAC.

Keywords: Pancreatic cancer, Precision oncology, MYC, Targeted therapies

Pancreatic Ductal Adenocarcinoma (PDAC)

Current estimates show that PDAC will be the second leading cause of cancer-related death reason by 2040 [1]. Together with a dismal prognosis reflected by a 5-year survival rate of 10% [2], these data imply the urgent need to intensify research into the disease. Approximately 85% of patients with PDAC are diagnosed with a locally advanced or disseminated disease that prevents surgical resection. For the small group of patients with a resectable tumor, adjuvant chemotherapy according to a modified regimen with folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) has been established and has improved overall survival [3]. Furthermore, neoadjuvant therapeutic regimens are in clinical development [3]. For the majority of patients with locally advanced or disseminated disease, systemic

chemotherapy with FOLFIRINOX or the combination of nab-paclitaxel and gemcitabine is used [4]. Although these therapies remain standard of care, overall response rates of only 20–30% and significant toxicities must be considered [4]. Therefore, the development of improved therapies is urgently required.

In contrast with the current “one-size-fits-all” clinical trials, precision oncology based on markers to guide therapy selections has the promises to improve outcomes. Precision oncology is also emerging in gastrointestinal (GI) cancers, and molecular profiling was recently highlighted by the American Society of Clinical Oncology (ASCO) as the advance of the year 2021 for GI cancers [5]. Examples include clinical trials in HER2 positive gastric cancer [6], the Viktory umbrella trial in gastric cancer [7], the approval of targeted therapies for cholangiocarcinomas with *FGFR2* fusions or rearrangements [8], or the use of a triple targeted therapy in *BRAF* mutated colon cancer [9]. Precise therapies have also been shown to affect PDAC patient survival [10]. Thus, further markers that characterize relevant PDAC subtypes, which are associated with specific drug responses, are needed. We propose the concept that the myelocytomatosis oncogene (MYC) is a relevant biomarker for PDAC. This is based

*Correspondence: guenter.schneider@med.uni-goettingen.de; matthias.wirth@charite.de

†Günter Schneider and Matthias Wirth have contributed equally to this work

¹ Medical Clinic and Policlinic II, Klinikum Rechts Der Isar, TU Munich, 81675 Munich, Germany

² German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany

Full list of author information is available at the end of the article

on the strong biology and specific phenotypes associated with MYC, the differential drug sensitivity of cancers with deregulated MYC, and the emerging ability to image MYC non-invasively.

An update of MYC-driven biology in PDAC

KRAS mutations occur in over 90% of PDACs [11] and MYC, a basic-helix-loop-helix/leucine zipper transcription factor (TF), has an important function as an integrator of signaling pathways triggered by oncogenic *KRAS* [12]. MYC heterodimers (e.g., MYC/MAX) bind to *cis*-regulatory E-box sequences of numerous genes involved in the regulation of growth, proliferation, or metabolism, thereby serving all hallmark demands of cancer cells [13, 14]. MYC marks an aggressive PDAC subtype, which is supported by the fact that amplifications of *MYC* have been associated with a worse survival of PDAC patients [15]. Pre-clinical experimental evidence underscores that MYC is an essential and non-redundant node of oncogenic signaling and therefore should be an exceptional therapeutic target [16–18]. We have recently summarized PDAC-specific functions of MYC [19–21] and therefore focus here on recent developments. The MYC network is activated in the so-called basal-like subtype, which is the most aggressive subtype and refractory to current therapies [22–26]. *MYC* amplifications occur more frequently in PDAC liver metastases, implicating a role of MYC in this process [27]. Interestingly, metastatic PDAC can be grouped into a low frequency metastasis group (<10 metastases) and high frequency metastasis (>10 metastases) group, with the high metastasis frequency group having lower overall survival [28]. Genomic and transcriptomic analyses linked MYC to the high metastasis group [28]. Furthermore, adenocarcinomas of the pancreas showed a high *MYC* amplification frequency [29].

In addition to its multiple implications in controlling cancer cell biology, MYC's important role in remodeling the tumor microenvironment (TME) is emerging. The TME is a unique feature of PDAC, evidenced by a prominent desmoplastic reaction that accounts for up to 90% of the tumor mass/volume [30]. Inducing *Myc* together with the *Kras* oncogene in murine *in vivo* PDAC models has an immediate and profound effect on the TME. This MYC-mediated TME-reprogramming is characterized by the attraction of immune cells such as macrophages, neutrophils, granulocytic myeloid-derived suppressor cells and B-cells, while CD3⁺ T-cells are depleted [31], collectively shaping an immunosuppressive phenotype. Consistently, MYC and BRAF synergistically drive immune-evasion downstream of *KRAS* [32], supporting a prominent role of MYC in

this process. In addition to the immune compartment, MYC instructs the proliferation of fibroblasts and stromal cells, leading to the characteristic tumor desmoplasia [31].

Mechanistically, a link of MYC to immune evasion in PDAC at different levels is described. Double-stranded RNA (dsRNA), derived from intronic inverted repetitive elements, activates the pattern recognition receptor TLR3 and its downstream effector, the serine-threonine kinase TANK-binding kinase 1 (TBK1) [33]. Here, MYC/MIZ1-mediated repression of vesicular transport genes result in decreased dsRNA secretion and consequently decreased activation of TLR3-TBK1-NF κ B signaling pathway, which is required for activation of the immune response by controlling the expression of MHC class I antigens [33]. Furthermore, paracrine signals, such as the GAS6-AXL pathway [31] or MYC-dependent repression of the type I interferon pathway [34], account for the TME remodeling. In addition, the folate cycle enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) was recently demonstrated to facilitate immune escape of PDAC cells. Mechanistically, MTHFD2 promotes the production of uridine diphosphate *N*-acetylglucosamine (UDP-GlcNAc), leading to O-GlcNAcylation of MYC, a post-translational modification (PTM), that results in its stabilization, and the subsequent increased expression of programmed cell death 1 ligand 1 (PD-L1), thereby blocking anti-tumor immune responses [35]. The effects of MYC on the TME have also been connected to the metastatic cascade. It was suggested that a panel of chemokines and cytokines upregulated in MYC overexpressing cells, including MIF, IL24, CCL4, CCL3, CXCL2, or CXCL3, contributes to the recruitment of pro-metastatic tumor-associated macrophages [28].

Importantly, a reciprocal stroma-to-tumor cell signaling is relevant. Here, a pathway is described in which the fibroblast growth factor receptor 1 (FGFR1) activated by FGF1-derived from cancer-associated fibroblasts (CAFs) is augmenting the tumor cell intrinsic MYC signal [36]. Furthermore, JAK1-STAT6-MYC-mediated increase in expression of enolase 1 and hexokinase (HK2)—enzymes involved in glycolysis—is promoted by IL4 and IL13 cytokines present in the TME, revealing the complex modalities of signals integrated by MYC [37]. In sum, MYC not only integrates *KRAS*-driven cellular signaling, but reciprocally controls communication with the TME to orchestrate the overall tumor biology. Taken together, this novel knowledge of how MYC shapes the TME additionally underscores its value as a therapeutic target and will open opportunities to implement immunotherapies in combination with concepts to block MYC.

MYC stratifies for therapies

Across all TF and cross-tumor entities, MYC exhibits the most frequent drug interactions [38]. This finding is based on several molecular features. The oncogenic addiction of cancer cells on MYC explains the increased sensitivity of cancer cells to drugs targeting MYC directly or indirectly. Furthermore, MYC-mediated oncogenic stress demands the activation of genes or pathways allowing the cancer cells to cope with. This renders cancer cells with deregulated MYC particularly sensitive to inhibitors of such pathways. The existence of MYC-associated synthetic dosage lethality is well documented by unbiased genetic and pharmacological screening experiments [39] and is relevant in the context of PDAC [21]. Genes allowing to tolerate MYC-induced oncogenic stress may be involved in feedforward regulatory circuits and blocking of such a gene also impacts on MYC expression. Importantly, MYC also marks resistance phenotypes that are currently emerging. Here, we summarize selected connections between MYC and drug sensitivity in PDAC cells.

Drug resistance and MYC

With regard to resistance phenotypes, MYC has been associated with modulation of the sensitivity of inhibitors of the serine/threonine protein kinase mammalian target of rapamycin (MTOR). MTOR is an important therapeutic target in PDAC, and combination therapies based on MTOR inhibitors (MTORi) are currently under development [40–44]. Genetic gain- and loss-of-function experiments demonstrated that MYC confers resistance to the MTORi INK128 (Sapanisertib) [45], a highly selective ATP-competitive inhibitor of the kinase under clinical development (e.g., NCT02197572, NCT02893930, NCT03430882). The MYC protein has a high turnover regulated by oncogenic signaling that cumulates in post-translational-modifications (PTMs) of the protein. KRAS induces stabilization of MYC through ERK-mediated phosphorylation of serine 62 (S62) [46]. The MYC-phospho-S62 counteracting protein phosphatase 2A (PP2A) de-phosphorylates S62, thereby initiating ubiquitin-dependent degradation of MYC. PP2A is a well-described regulator of MYC protein expression in PDAC [47]. Consequently, small-molecules activators of PP2A, like DT1154 [48], synergize with the MTORi INK128 in PDAC *in vitro* and *in vivo* models [45].

Additionally, also secondary resistance phenotypes to targeted therapies may also be mediated by MYC. Interference with the canonical KRAS-MEK-ERK signaling induced downregulation of MYC protein expression. Therefore, MEKi perturbs MYC-directed and pentose phosphate pathway (PPP)-mediated nucleotide synthesis with a subsequent growth arrest. Interestingly, in PDAC

cells generated as MEKi resistant, MYC escaped regulation and maintained nucleotide synthesis contributing to the resistance phenotype [49].

MYC-induced resistance occurs not only to targeted therapies, but also with conventional chemotherapeutic agents. MYC has been shown to promote epithelial-neuroendocrine lineage plasticity, a state characterized by the increased expression of neuroendocrine markers, like synaptophysin, and resistance to gemcitabine [50]. Lowering MYC expression by an RNA interference approach increased the sensitivity of PDAC cells to gemcitabine [50]. In addition to primary chemotherapy resistance, MYC has been shown to be involved in secondary resistance to paclitaxel [51]. Low-passaged primary PDAC cultures and a ramp-up protocol to induce paclitaxel resistance were used to generate secondary resistant models. Analysis of the models illustrated increased expression of MYC mRNA and protein expression. Furthermore, reduction in MYC expression increased paclitaxel-induced cell death in the resistant lines, whereas overexpression reduced paclitaxel-induced cell death in the parental PDAC cells [51]. Interestingly, gemcitabine was found to trigger a MYC-associated vulnerability in unbiased screening experiments [38, 52, 53] and deregulated MYC sensitizes to mitotic perturbants, including paclitaxel [54, 55]. Such data highlight the need for further research on MYC-associated vulnerabilities and point to a specific context, exemplified here by lineage or secondary versus primary resistance, that needs to be understood.

Targeting MYC in PDAC

Direct targeting of MYC remains a challenge and no small molecule inhibitor has made it to the clinic so far [13, 56]. Due to recent developments, we will only shortly describe OMOMYC, a dominant negative MYC dimerization inhibitor. OMOMYC, a 91 amino acids mutant version of the MYC dimerization domain, prevents MYC from binding to its target genes. In several cancer mouse models, conditional expression of OMOMYC dramatically impacts on tumor growth [17, 57, 58]. *In vitro*, an inducible OMOMYC reduced the clonogenic growth of murine PDAC cell lines [59]. The concept was recently advanced by the development of an OMOMYC mini-protein. The *in vivo* efficacy of the mini-protein was demonstrated in non-small cell lung cancer (NSCLC) models [18]. The mini-protein penetrates many organs, including the pancreas [18]. Importantly, a phase I/II clinical trial of the OMOMYC mini-protein (OMO-103) was started in 2021 (NCT04808362), bringing direct MYC inhibition to the clinic. In addition to OMOMYC mini-proteins, it is foreseeable that advanced drug development methods, such as the proteolysis targeting chimera (PROTAC)

technology, will lead to the development of clinical candidates that directly and specifically targeting MYC (Fig. 1) [60].


Several approaches to indirectly target MYC expression exist, and we will summarize some with documented relevance in PDAC (Fig. 1). Members of the bromo- and extra-terminal domain (BET) motif protein family, BRD2, BRD3, BRD4, and BRDT, are involved in the regulation of many cancer-relevant pathways, and BET inhibitors (BETi) are in clinical development [61]. Expression of cancer driver genes is often regulated by so-called super-enhancers (SE), specialized *cis*-acting regulatory elements characterized by an enriched acetylation of histone H3 lysine 27 (H3K27ac), which stimulate high-level expression of associated genes. These enhancers are particularly sensitive to BETi [62] so that oncogenic drivers, including MYC, can be inhibited. Inhibition of MYC expression by BETi has also been documented in PDAC [63]. In primary patient-derived xenografts, a less differentiated PDAC subtype, with a high proliferation index and shorter survival, was characterized [64]. This subtype was characterized by a MYC-driven transcriptional program and sensitivity to BETi [64]. The study was recapitulated in human PDAC organoids, a model with a potential predictive power for the clinical behavior of solid cancers [65]. Again, the defined MYC-signature co-segregates with higher sensitivity to the BETi JQ1 and NHWD-870 [66].

In addition to BETi, inhibitors of histone deacetylases (HDAC) target MYC expression and the MYC-driven transcriptional program in PDAC [67]. Furthermore, HDAC were shown to tune the MYC program and repress a gene program linked to epithelial differentiation

[68]. Blocking HDAC function by inhibitors induces these genes in a BRD4-dependent fashion [68], furthermore underlining the close interplay between HDAC and BET proteins. Such connections might contribute to the described synergism of BETi and HDACi in patient-derived xenograft models and are underpinned by the profound effect of the combined inhibition of HDACs and BET on MYC protein expression [63]. Recently dual BET/HDAC inhibitors were developed and tested in PDAC models. Notably, after prolonged treatment, TW9, a dual BET/HDACi, distinctly reduced MYC expression [69]. However, other SE-controlled cancer drivers, including the AP1-TF family member *FOSL1*, also appear to be targeted by TW9 [69].

The ATP-dependent DNA helicase excision repair cross-complementation protein 3 (ERCC3) is a component of the general transcription factor TFIIF, which is part of the transcriptional preinitiation complex (Fig. 1). ERCC3 can be targeted by the natural diterpenoid epoxide triptolide [70]. In an unbiased pharmacological screening experiment, high activity of triptolide for PDAC was found. Mechanistically, triptolide reduced MYC mRNA and protein expression [71] by disrupting the activity of SE and causing downregulation of associated genes, including MYC [72]. The high efficacy of triptolide has been demonstrated in *in vitro* and *in vivo* models of PDAC with deregulated MYC expression [71], allowing to tackle this particular subtype.

In addition to transcriptional or post-translational interference with MYC, the translation of MYC can also be pharmacologically disrupted (Fig. 1). The mRNA of MYC harbors a structured 5'UTR, which is characteristic for translation controlled by the RNA helicase eukaryotic



initiation factor 4A (eIF4A) [73]. Therefore, the use of eIF4A inhibitors to impair MYC expression in PDAC is an attractive option. The eIF4A inhibitor CR-1-31B demonstrated high efficacy both in vivo and in vitro [73, 74]. This class of inhibitors (e.g., zotatifine) is currently being tested in a phase 1–2 clinical trial in PDAC patients (NCT04092673). Consistent with the complex cross-talk of MYC with the TME, the natural eIF4A inhibitor silvestrol augmented the activity of an anti-PD1 antibody therapy [75].

The peptidyl-prolyl cis–trans isomerase NIMA-interacting 1 (PIN1), which induces conformational changes in certain phosphorylated proteins, is overexpressed in many cancers [76]. Proline-guided serine or threonine phosphorylation is a typical PTM, conducted by kinases like ERK or cyclin-dependent kinases (CDKs). PIN1 complexes with serine 62-phosphorylated MYC leading to trans > cis isomerization of proline 63 [77], which prevents phosphatase activity and an increased DNA binding capacity of MYC. Genetic gain- and loss-of-function experiments have demonstrated that the transcriptional output of MYC is controlled by PIN1 [78]. Recently the covalent, highly selective PIN1 inhibitor sulfopin was shown to downregulate the MYC transcriptional network [79]. Interestingly, sulfopin reduced PDAC growth and prolonged survival in an immune-proficient orthotopic transplantation model in vivo [79].

Targeting MYC-associated vulnerabilities

MYC renders cancer cells dependent on a properly functioning transcriptional machinery [80]. Initiation, pausing, and elongation of the RNA polymerase II (Pol II) are tightly controlled. One control mechanism is integrated by phosphorylation of the carboxy-terminal domain (CTD) of the largest subunit of Pol II, with the CTD integrating the activity of the transcriptional CDKs, like CDK7 or CDK9 [81]. CDK7 acts at multiple sites in the transcriptional cycle and is involved in Pol II-dependent transcriptional entry as well as in the activation of CDK9, involved in transcriptional pause release [81]. A pharmacological screening of epigenetic drugs in human PDAC cell lines revealed the CDK7i THZ1 as a prominent hit. The sensitivity of THZ1 strongly correlated with MYC expression and the activity of the associated network [82]. Selective CDK7 inhibitors, such as the orally available CDK7i CT7001 or SY-5609, are currently tested in clinical trials in patients with solid cancers (NCT03363893, NCT04247126), demonstrating the clinical potential. In addition to CDK7, higher activity of CDK9i in cancers with deregulated MYC is already known [83]. In PDAC, the connection of CDK9i (UNC10112785) to MYC was recently found in a screen using a MYC degradation reporter system. In addition to the decrease in MYC

mRNA, CDK9 was shown to induce phosphorylation of serine 62 and thus MYC stability, arguing for a feed forward loop [84].

A drug screening of FDA approved anti-cancer drugs and analysis of several public repositories revealed an increased sensitivity toward perturbations of the protein homeostasis in MYC^{high} PDAC cells [52]. MYC orchestrates a variety of biological processes by regulating and tuning the transcriptional and translational output [85]. Due to the high amount of protein load in cancer cells and a protein biosynthesis machinery acting at the upper limit, cells with high MYC expression are associated with an increased unfolded protein response (UPR). The strong connection of MYC activity and the UPR is also documented across species [86] and cancer entities [87, 88], explaining increased sensitivity to perturbations in protein homeostasis.

A recent study connected MYC to PDAC with increased expression of the small ubiquitin-like modifier (SUMO)-ylation machinery [89]. The enzymatic cascade of SUMOylation is analogous to ubiquitination, which consists of a single heterodimeric SUMO activating enzyme (E1), a single SUMO conjugating enzyme (E2), and less well-defined SUMO ligases (E3) [21, 88]. Recently, pharmacological SUMO inhibition was shown to be particularly potent in PDAC cells, which are characterized by high MYC activity [89]. This synthetic lethality has already been demonstrated in other entities [90–92] and demonstrated a MYC-dependent and entity-independent vulnerability. SUMO inhibitors such as Subasumstat (TAK-981) are currently under clinical development in advanced solid cancers (NCT04381650).

Imaging MYC in PDAC

Considering the strong association of MYC with drug responsive states, non-invasive imaging-based biomarkers indicative for activity of MYC will help to stratify PDAC patients for specific therapies. Nearly three decades ago, Indium-111-labeled antisense-oligonucleotides were used to measure MYC mRNA in breast cancer mouse models [93]. However, this imaging method revealed hurdles, such as limited tracer delivery due to physical barriers, target sequence selection, or low stability [94]. In 2012, the radiotracer ⁸⁹Zirconium (Zr)-desferrioxamine transferrin (⁸⁹Zr-Tf) was developed and ⁸⁹Zr-Tf PET imaging was shown to annotate the MYC status [95]. The transferrin receptor (TfR1, TFRC, CD71; TFRC afterwards) is a transmembrane glycoprotein, which acts as a disulfide bond-linked dimer. Transferrin, bound by two iron atoms, shows the highest affinity for the TFRC, and upon binding, transferrin and the receptor are internalized by endocytosis and iron replenish the intracellular pools [96]. Iron is needed for many cellular

processes serving the demands of cancer cells, including mitochondrial respiration to generate energy, building of ribonucleotides for DNA synthesis, or DNA repair [96]. MYC directly activates the *TFRC* gene (Fig. 2) to serve the iron demands of aggressive cancers [97], allowing to indirectly image its activity. Initially ^{89}Zr -Tf PET imaging was developed to annotate MYC in prostate cancer models [95]. Meanwhile, this imaging modality was demonstrated to define the MYC status in other tumor entities, like triple negative breast cancer models [98] and allows monitoring of treatment induced changes of MYC expression (Fig. 2) [99]. ^{89}Zr -Tf PET imaging was also evaluated in PDAC models and determines the extent of the KRAS signaling output and the downstream integrator MYC [100]. Furthermore, the imaging modality was shown to be useful to monitor pharmacological interference with pathways integrated by MYC or drugs which target MYC [100].


Alternatives to the ^{89}Zr -Tf PET imaging were also developed. A human anti-transferrin receptor monoclonal antibody labeled with ^{89}Zr as a PET probe was investigated in PDAC and shown to allow measurement of the TFRC in xenograft models [101]. In addition, ^{68}Ga -citrate, which binds to transferrin, can be used to image the TFRC (Fig. 2) [102]. In prostate cancer models, PET imaging with the tracer ^{68}Ga -citrate was shown to

substitute the ^{89}Zr -Tf PET imaging and some hints of the association of the signal with MYC deregulated cancers were provided [103], increasing the number of imaging modalities to annotate MYC. However, a combination of different imaging and genetic approaches may allow more precise stratification and further prospective studies are needed to validate MYC centric imaging modalities.

Conclusions

Successful concepts for precision oncology require strong drivers of cancer subtypes as biomarkers, that are associated with different drug sensitivity phenotypes, like MYC. However, multiple layers of such an approach need to be advanced, from a better understanding of the MYC-associated drug response to modalities for mapping MYC activity.

Current markers of drug responsiveness only enrich for a responding population, and even cancer stratified by MYC will only increase the proportion of patients who respond to a particular therapy. Therefore, the drug response in PDACs with high MYC activity that does not respond to therapies and trigger associated vulnerability needs to be better characterized and will lead to bi- or trivalent selection markers and molecular combination therapies. Therefore, the context in which MYC operates needs to be better defined experimentally.



Molecular and functional imaging also needs to evolve, and the integration of multimodal imaging can increase the precision in terms of biomarkers and targets. Since MYC is a central regulator of glycolysis and regulates the transcription of glycolytic genes, such as *HK2*, *ENO1*, *LDHA*, *SLC2A1* [104, 105], glycolysis might be used as surrogate and an indirect imaging approach to determine MYC activity. In a MYC-inducible model of liver cancer, glycolysis could be visualized by hyperpolarized ^{13}C magnetic resonance spectroscopy and its activity could be attributed to the MYC oncogene [106]. In breast cancer, ^{18}F -FDG PET can image basal-like cancers with deregulated MYC [107]. Glycolysis- and MYC-networks enrich in basal-like PDAC [11], offering an additional opportunity for imaging. As a future example of a multimodal imaging approach, ^{18}F -FDG PET combined with imaging of the MYC-TFRC circuit might enable a more accurate discrimination of basal-like subtypes with deregulated MYC. However, other oncogenic pathways, particularly the PI3K-AKT pathway [108] or hypoxia-mediated activation of the hypoxia-inducible factor 1 (HIF) [109], have also been shown to induce glycolysis. Therefore, there is a definite need for more pre-clinical evidence of such concepts followed by prospective clinical evaluation. In addition, such clinical non-invasive imaging modalities demand to be accompanied by longitudinal biopsy programs to link imaging with molecular features. Finally, more direct non-invasive MYC imaging modalities should be developed. Interestingly, the OMOMYC mini-protein labeled with ^{89}Zr (Omomyc-deferoxamin-maleimide(DFO)- ^{89}Zr) was shown to accumulate in mouse lung tumors after intranasal application [18], which will allow further development of OMOMYC mini-proteins into imaging probes for annotation of MYC status as well as for cancer theranostics.

Acknowledgements

We apologize for not citing any relevant reports due to the need to selectively choose examples, a lack of space, or an oversight on our part. Drawing tools from motifolio.com.

Authors' contributions

All authors involved in conception and design of the article; interpretation of data; drafting of the manuscript; revised the manuscript for important intellectual content; and approved the final version submitted for publication.

Funding

Open Access funding enabled and organized by Projekt DEAL. DFG-SFB824 Project C9 to G.S. and D.S. and Project C3 to U.K.; DFG-SFB1321 (Project-ID 329628492) to G.S. and D.S., DFG-SCHN959/3-2 and SCHN959/6-1 to G.S., Deutsche Krebshilfe (70113760 to G.S., 70114425 to U.K.), Wilhelm Sander Stiftung (2017.048.2 to G.S. and U.K. and 2019.086.1 to G.S.). A Stiftung Charité research grant to U.K. The funding agencies had no influence on any aspect of the study.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Ulrich Keller has served in an advisory role for Takeda unrelated to the content of this manuscript. The other authors declare no competing interests.

Author details

¹Medical Clinic and Policlinic II, Klinikum Rechts Der Isar, TU Munich, 81675 Munich, Germany. ²German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. ³Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, 37075 Göttingen, Germany. ⁴Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, 12203 Berlin, Germany. ⁵Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany. ⁶Institute for Translational Cancer Research and Experimental Cancer Therapy, MRI, TU Munich, 81675 Munich, Germany.

Received: 4 June 2021 Accepted: 23 September 2021

Published online: 12 October 2021

References

- Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US Cancer incidence and death to 2040. *Jama Netw Open*. 2021;4:e214708.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *Ca Cancer J Clin*. 2021;71:7–33.
- Mavros MN, Moris D, Karanicolos PJ, Katz MHG, O'Reilly EM, Pawlik TM. Clinical trials of systemic chemotherapy for resectable pancreatic cancer. *Jama Surg*. 2021;156.
- Smithy JW, O'Reilly EM. Pancreas cancer: therapeutic trials in metastatic disease. *J Surg Oncol*. 2021;123:1475–88.
- Smith SM, Wachter K, Burris HA, Schilsky RL, George DJ, Peterson DE, et al. Clinical cancer advances 2021: ASCO's report on progress against cancer. *J Clin Oncol*. 2021;39:1165–84.
- Roviello G, Aprile G, D'Angelo A, Iannone LF, Roviello F, Polom K, et al. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? *Gastric Cancer*. 2021;1–15.
- Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. *Cancer Discov*. 2019;9:1388–405.
- Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2020;21:671–84.
- Kopetz S, Grothey A, Yaeger R, Cutsem EV, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. *New Engl J Med*. 2019;381:1632–43.
- Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. *Lancet Oncol*. 2020;21:508–18.
- Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. *Nat Rev Gastroenterol*. 2019;16:207–20.
- Schneeweis C, Wirth M, Saur D, Reichert M, Schneider G. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—a connection to licensing nodes. *Small Gtpases*. 2017;9:457–64.
- Wolf E, Eilers M. Targeting MYC proteins for tumor therapy. *Annu Rev Cancer Biol*. 2020;4:61–75.

14. Ross J, Miron CE, Plescia J, Laplante P, McBride K, Moitessier N, et al. Targeting MYC: from understanding its biology to drug discovery. *Eur J Med Chem.* 2020;213:113137.
15. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin W-C, Mansour J, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. *Nat Commun.* 2015;6:6744.
16. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the “undruggable” cancer targets. *Nat Rev Cancer.* 2017;17:502–8.
17. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. *Nature.* 2008;455:679–83.
18. Beaulieu M-E, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. *Sci Transl Med.* 2019;11:ear5012.
19. Wirth M, Mahboobi S, Kraemer OH, Schneider G. Concepts to Target MYC in Pancreatic Cancer. *Mol Cancer Ther.* 2016;15:1792–8.
20. Wirth M, Schneider G. MYC: a stratification marker for pancreatic cancer therapy. *Trends Cancer.* 2016;2:1–3.
21. Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G. The SUMO pathway in pancreatic cancer: insights and inhibition. *Br J Cancer.* 2021;124:531–8.
22. Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature.* 2016;531:47–52.
23. Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O’Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. *Nat Genet.* 2020;52:231–40.
24. Aung KL, Fischer SE, Denroche RE, Jang G-H, Dodd A, Creighton S, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. *Clin Cancer Res.* 2017;24:clincanres.2994.2017.
25. Muckenhuber A, Berger AK, Schlitter AM, Steiger K, Konukiewicz B, Trumpp A, et al. Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1A and cytokeratin-81 correlates with outcome and treatment response. *Clin Cancer Res.* 2017;24:1344–54.
26. Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. *Nat Med.* 2016;22:278–87.
27. Brar G, Blais EM, Bender RJ, Brody JR, Sohal D, Madhavan S, et al. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. *Br J Cancer.* 2019;121:264–70.
28. Maddipati R, Norgard RJ, Baslan T, Rathi KS, Zhang A, Raman P, et al. MYC controls metastatic heterogeneity in pancreatic cancer. *Biorxiv.* 2021;2021.01.30.428641.
29. Lenkiewicz E, Malasi S, Hogenson TL, Flores LF, Barham W, Phillips WJ, et al. Genomic and epigenomic landscaping defines new therapeutic targets for adenocarcinoma of the pancreas. *Cancer Res.* 2020;80:4324–34.
30. Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, et al. Microenvironmental determinants of pancreatic cancer. *Physiol Rev.* 2020;100:1707–51.
31. Sodir NM, Kortlever RM, Barthel VJA, Campos T, Pellegrinet L, Kupczak S, et al. Myc instructs and maintains pancreatic adenocarcinoma phenotype. *Cancer Discov.* 2020;10:588–607.
32. Ischenko I, D’Amico S, Rao M, Li J, Hayman MJ, Powers S, et al. KRAS drives immune evasion in a genetic model of pancreatic cancer. *Nat Commun.* 2021;12:1482.
33. Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, et al. MYC- and MIZ1-dependent vesicular transport of double-strand RNA controls immune evasion in pancreatic ductal adenocarcinoma. *Cancer Res.* 2021;canres.CAN-21-1677-E.2021.
34. Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, et al. Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma. *Cancer Discov.* 2020;10:872–87.
35. Shang M, Yang H, Yang R, Chen T, Fu Y, Li Y, et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. *Nat Commun.* 2021;12:1940.
36. Bhattacharyya S, Oon C, Kothari A, Horton W, Link J, Sears RC, et al. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. *J Exp Med.* 2020;217(8):e20191805.
37. Dey P, Li J, Zhang J, Chaurasiya S, Strom A, Wang H, et al. Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment. *Cancer Discov.* 2020;10:608–25.
38. Garcia-Alonso L, Iorio F, Matchan A, Fonseca N, Jaaks P, Peat G, et al. Transcription factor activities enhance markers of drug sensitivity in cancer. *Cancer Res.* 2017;78:769–80.
39. Thng DKH, Toh TB, Chow EK-H. Capitalizing on synthetic lethality of MYC to treat cancer in the digital age. *Trends Pharmacol Sci.* 2021;42:166–82.
40. Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B, et al. mTOR inhibitor-based combination therapies for pancreatic cancer. *Br J Cancer.* 2018;118:366.
41. Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. *Gut.* 2019;68:742.
42. Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, et al. mTORC2 signaling drives the development and progression of pancreatic cancer. *Cancer Res.* 2016;76:6911–23.
43. Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, et al. Targeting mTOR dependency in pancreatic cancer. *Gut.* 2014;63:1481.
44. Knudsen ES, Kumarasamy V, Ruiz A, Sivinski J, Chung S, Grant A, et al. Cell cycle plasticity driven by mTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. *Oncogene.* 2019;38:3355–70.
45. Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, et al. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. *Cancer Res.* 2018;79:209–19.
46. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Gene Dev.* 2000;14:2501–14.
47. Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, et al. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. *Mol Cancer Res.* 2014;12:924–39.
48. Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. *J Clin Invest.* 2017;127:2081–90.
49. Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. *Nat Commun.* 2018;9:4945.
50. Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, et al. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. *Nat Commun.* 2017;8:1728.
51. Parasido E, Avetian G, Naeem A, Graham G, Pishvaian M, Glasgow E, et al. The sustained induction of c-Myc drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells. *Mol Cancer Res.* 2019;17:1815–27.
52. Lankes K, Hassan ZZ, Doffo MJ, Schneeweis C, Lier S, Öllinger R, et al. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. *Mol Oncol.* 2020;14:3048–64.
53. Wang J, Jiang J, Chen H, Wang L, Guo H, Yang L, et al. FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. *Oncogene.* 2019;38:6737–51.
54. Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L, et al. MYC is a major determinant of mitotic cell fate. *Cancer Cell.* 2015;28:129–40.
55. Littler S, Sloss O, Geary B, Pierce A, Whetton AD, Taylor SS. Oncogenic MYC amplifies mitotic perturbations. *Open Biol.* 2019;9:190136.
56. Allen-Petersen BL, Sears RC. Mission possible: advances in MYC therapeutic targeting in cancer. *BioDrugs.* 2019;33:539–53.
57. Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, et al. Inhibition of Myc family proteins eradicates KRAS-driven lung cancer in mice. *Gene Dev.* 2013;27:504–13.
58. Annibaldi D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. *Nat Commun.* 2014;5:4632.

59. Jung LA, Gebhardt A, Koelmel W, Ade CP, Walz S, Kuper J, et al. OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. *Oncogene*. 2017;36:1911–24.
60. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. *Cell*. 2020;181:102–14.
61. Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. *Br J Cancer*. 2021;1–13.
62. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell*. 2013;153:320–34.
63. Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. *Nat Med*. 2015;21:1163–71.
64. Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilbert M, et al. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. *Embo Mol Med*. 2017;9:482–97.
65. Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF, Kranenburg OW, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. *Npj Precis Oncol*. 2021;5:30.
66. Bian B, Juiz NA, Gayet O, Bigonnet M, Brandone N, Roques J, et al. Pancreatic cancer organoids for determining sensitivity to bromodomain and extra-terminal inhibitors (BETi). *Frontiers Oncol*. 2019;9:475.
67. Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schäfer C, et al. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. *Oncogene*. 2016;36:1804–15.
68. Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. *Nucleic Acids Res*. 2017;45:gx212-.
69. Zhang X, Zegar T, Weiser T, Hamdan FH, Berger B, Lucas R, et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. *Int J Cancer*. 2020;147:2847–61.
70. Titov DV, Gilman B, He Q-L, Bhat S, Low W-K, Dang Y, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. *Nat Chem Biol*. 2011;7:182–8.
71. Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Brovov E, et al. Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3–MYC interactions as a target in pancreatic cancer. *Clin Cancer Res*. 2016;22:6153–63.
72. Noel P, Hussein S, Ng S, Antal CE, Lin W, Rodela E, et al. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. *Oncogenesis*. 2020;9:100.
73. Singh K, Lin J, Lecomte N, Mohan P, Gokce A, Sanghvi VR, et al. Targeting eIF4A-dependent translation of KRAS signaling molecules. *Cancer Res*. 2021;81:2002–14.
74. Chan K, Robert F, Oertlin C, Kapeller-Liebermann D, Avizonis D, Gutierrez J, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. *Nat Commun*. 2019;10:5151.
75. Hashimoto A, Handa H, Hata S, Tsutahō A, Yoshida T, Hirano S, et al. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. *Cell Commun Signal*. 2021;19:54.
76. Chen Y, Wu Y, Yang H, Li X, Jie M, Hu C, et al. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. *Cell Death Dis*. 2018;9:883.
77. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. *Nat Cell Biol*. 2004;6:308–18.
78. Farrell AS, Pelz C, Wang X, Daniel CJ, Wang Z, Su Y, et al. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. *Mol Cell Biol*. 2013;33:2930–49.
79. Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, et al. Sulfolin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. *Nat Chem Biol*. 2021;1–10.
80. Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. *Cell*. 2017;168:629–43.
81. Parua PK, Fisher RP. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors. *Nat Chem Biol*. 2020;16:716–24.
82. Lu P, Geng J, Zhang L, Wang Y, Niu N, Fang Y, et al. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. *Oncogene*. 2019;38:3932–45.
83. Huang C-H, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. *Gene Dev*. 2014;28:1800–14.
84. Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. *Sci Signal*. 2019;12:eaav7259.
85. Wolpaw AJ, Dang CV. MYC-induced metabolic stress and tumorigenesis. *Biochimica Et Biophysica Acta Bba Rev Cancer*. 2018;1870:43–50.
86. Nagy P, Varga Á, Pircs K, Hegedűs K, Juhász G. Myc-driven overgrowth requires unfolded protein response-mediated induction of autophagy and antioxidant responses in drosophila melanogaster. *PLoS Genet*. 2013;9:e1003664.
87. Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. *J Clin Invest*. 2012;122:4621–34.
88. Wirth M, Schick M, Keller U, Krönke J. Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy. *Cancers*. 2020;12:3764.
89. Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. *Gut*. 2020;124:531–8.
90. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. *Science*. 2012;335:348–53.
91. Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. *Blood*. 2014;124:2081–90.
92. He X, Riceberg J, Soucy T, Koenig E, Minissale J, Gallery M, et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. *Nat Chem Biol*. 2017;13:1164–71.
93. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, Dewanjee S, Serafini AN, Lopez DM, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. *J Nucl Med*. 1994;35:1054–63.
94. Iyer AK, He J. Radiolabeled oligonucleotides for antisense imaging. *Curr Org Synth*. 2011;8:604–14.
95. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. *Nat Med*. 2012;18:1586–91.
96. Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. *Front Immunol*. 2021;12:607692.
97. O'Donnell KA, Yu D, Zeller KI, Kim J, Racke F, Thomas-Tikhonenko A, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis†. *Mol Cell Biol*. 2006;26:2373–86.
98. Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. Noninvasive 89 Zr-transferrin PET shows improved tumor targeting compared with 18 F-FDG PET in MYC-overexpressing human triple-negative breast cancer. *J Nucl Med*. 2017;59:51–7.
99. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, et al. Applying 89Zr-transferrin to study the pharmacology of inhibitors to BET bromodomain containing proteins. *Mol Pharm*. 2016;13:683–8.
100. Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, et al. A PET imaging strategy for interrogating target engagement and oncogene status in pancreatic cancer. *Clin Cancer Res*. 2018;25(25):166–76.
101. Sugyo A, Tsuji AB, Sudo H, Nagatsu K, Koizumi M, Ukai Y, et al. Preclinical evaluation of 89Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model. *Nucl Med Commun*. 2015;36:286–94.
102. Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. *J Natl Cancer*. 1980;(64):41–53.
103. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, et al. Real-time transferrin-based PET detects MYC-positive prostate cancer. *Mol Cancer Res*. 2017;15:1221–9.

104. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc*. *J Biol Chem*. 2000;275:21797–800.
105. Kim J, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O'Donnell KA, et al. Evaluation of Myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays†. *Mol Cell Biol*. 2004;24:5923–36.
106. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PEZ, Nelson SJ, et al. ¹³C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. *Cell Metab*. 2011;14:131–42.
107. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, et al. ¹⁸F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. *Cancer Res*. 2011;71:5164–74.
108. Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. *Nat Rev Cancer*. 2020;20:74–88.
109. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. *Nat Rev Cancer*. 2008;8:705–13.
110. Gerstner N, Kehl T, Lenhof K, Müller A, Mayer C, Eckhart L, et al. GeneTrail 3: advanced high-throughput enrichment analysis. *Nucleic Acids Res*. 2020;48:gkaa306.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
